Ye Maogen, Hao Pingsheng, Luo Nana, Li Tianhao
Department of Dermatology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, 610000, People's Republic of China.
Chengdu University of Traditional Chinese Medicine, Chengdu, 610000, People's Republic of China.
Clin Cosmet Investig Dermatol. 2025 Jun 12;18:1459-1470. doi: 10.2147/CCID.S525787. eCollection 2025.
Rosacea is a common dermatological disease, and the complexity of its etiology and pathogenesis makes conventional treatment of rosacea difficult. Small-molecule drugs are a new option for the treatment of rosacea. Based on its good efficacy, convenience of use, affordable price and other advantages, more and more small-molecule drugs are used in the treatment and management of rosacea, involving a variety of molecular pathways, including JAK/STAT signaling pathway, TRPV, TLR2-KLK5-LL37 and mTOR pathways, Th1/Th17-IL17, PED-4, AhR and MRGPRX2. However, the specific treatment mechanism and research progress have not been systematically elucidated. This review summarizes the latest advances in small molecules targeting key inflammatory pathways in rosacea, provides new ideas for the treatment of rosacea and new directions for the clinical management of rosacea. In addition, we need to pay attention to individual differences in patients, the side effects of drugs and formulations. Therefore, further research on small-molecule drugs for the treatment of rosacea is very necessary.
酒渣鼻是一种常见的皮肤病,其病因和发病机制的复杂性使得酒渣鼻的传统治疗颇具难度。小分子药物是治疗酒渣鼻的一种新选择。基于其良好的疗效、使用便利性、价格可承受性等优势,越来越多的小分子药物被用于酒渣鼻的治疗和管理,涉及多种分子途径,包括JAK/STAT信号通路、瞬时受体电位香草酸亚型(TRPV)、Toll样受体2-激肽释放酶5-抗菌肽LL37和雷帕霉素靶蛋白(mTOR)途径、辅助性T细胞1/辅助性T细胞17-白细胞介素17、磷酸二酯酶4(PED-4)、芳烃受体(AhR)和 Mas相关G蛋白偶联受体X2(MRGPRX2)。然而,具体的治疗机制和研究进展尚未得到系统阐明。本综述总结了针对酒渣鼻关键炎症途径的小分子的最新进展,为酒渣鼻的治疗提供新思路,为酒渣鼻的临床管理提供新方向。此外,我们需要关注患者的个体差异、药物的副作用和剂型。因此,进一步研究治疗酒渣鼻的小分子药物非常必要。